Oct 31, 2009 | PharmaExec.com
Sanofi Warned for Misleading Tent Card
Sanofi-Aventis received a warning letter from the FDA's division of drug marketing, advertising, and communications after the company distributed a misleading promotional card for Uroxatral, an alpha1-blocker used to treat urinary problems caused by an enlarged prostate.
FDA Sends Letter to Sanofi-Aventis Regarding Uroxatral Promotion
The FDA today posted on its website a letter sent to Sanofi-Aventis regarding a voucher tent card for Uroxatral.
Sanofi-Aventis (France) Gets FDA Warning Over Uroxatral Promotion
The U.S. Food and Drug Administration has sent a warning letter to Sanofi-Aventis accusing the French drugmaker of distributing misleading promotional material on its Uroxatral treatment for urinary problems caused by an enlarged prostate.
FDA approves Wockhardt's prostate drug
Alfuzosin is the generic name for Uroxatral, marketed in the USA by French pharmaceutical company Sanofi-Aventis SA .
Also on Topix